Results 271 to 280 of about 134,892 (289)
Some of the next articles are maybe not open access.
Genes, Chromosomes and Cancer, 1991
AbstractWe report a new class of molecular lesions in the 5′ region of the BCL2 protooncogene when it undergoes a t(14;18) translocation‐associated rearrangement in the major break cluster (MBR) or minor break cluster (MCR) regions. Among 52 tumors assayed for BCL2 rearrangements using the MBR, MCR, and 5′ probes, seven (six with MBR and one with MCR ...
Marc Ladanyi +3 more
openaire +3 more sources
AbstractWe report a new class of molecular lesions in the 5′ region of the BCL2 protooncogene when it undergoes a t(14;18) translocation‐associated rearrangement in the major break cluster (MBR) or minor break cluster (MCR) regions. Among 52 tumors assayed for BCL2 rearrangements using the MBR, MCR, and 5′ probes, seven (six with MBR and one with MCR ...
Marc Ladanyi +3 more
openaire +3 more sources
Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction
Biochemical Pharmacology, 2017Apoptosis is a highly regulated pathway of programmed cell death relying on the fine balance between pro and antiapoptotic binding partners. Overexpression of the antiapoptotic protein BCL2 in several cancers makes it an ideal target for chemotherapy, with minimum side effects.
Avadhesha Surolia +11 more
openaire +2 more sources
[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019Objective: To investigate the strong expression (S+) of P53 and BCL2 proteins in MYC/BCL2 double-expression DLBCL (DEL) and whether they can be used for the prognostic evaluation and stratified diagnosis of DELs. Methods: Tissue microarray were made by filed FFPE blocks of 174 DLBCL cases.
Yuanyuan Lei +11 more
openaire +2 more sources
Enhancing dendritic cells by inhibiting BCL2
Trends in Cancer, 2023Dendritic cells play an important role in anticancer immunity by exposing T cells to tumor-associated antigens. In a recent study, Zhao et al. show that BCL2 inhibition improves the ability of dendritic cells to present antigen to T cells and activate their antitumor cytotoxicity.
Christopher A G, Booth, Andrew A, Lane
openaire +2 more sources
Therapeutic Targeting of the Bcl2 Family
Blood, 2013Abstract Many, perhaps most, cancer chemotherapy agents kill cancer cells via the mitochondrial pathway of apoptosis that is controlled by the Bcl-2 family of proteins. Bcl-2 family proteins regulate commitment to cell death by controlling mitochondrial outer membrane permeabilization (MOMP).
Anthony Letai +4 more
openaire +2 more sources
BCL2: A promising cancer therapeutic target
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017A remarkable characteristic of majority of cancer cells is that, they fail to undergo apoptosis, which in turn confers them a survival advantage over normal cells. Targeted cancer therapy aims at disrupting the functions of proteins that play an important role during cancer progression.
Radha, Gudapureddy, Raghavan, Sathees C
openaire +4 more sources
Pathology - Research and Practice, 2016
Follicular lymphomas are characterized by overexpression of BCL2 which, in the large majority of cases, is due to a t(14;18) translocation which juxtaposes the BCL2 locus to the immunoglobulin heavy chain locus (IGH). Here, we report partial absence of BCL2 immunohistochemical staining in a case of FL, due to a mutation in the part of BCL2 that encodes
Brand, M. van den +6 more
openaire +4 more sources
Follicular lymphomas are characterized by overexpression of BCL2 which, in the large majority of cases, is due to a t(14;18) translocation which juxtaposes the BCL2 locus to the immunoglobulin heavy chain locus (IGH). Here, we report partial absence of BCL2 immunohistochemical staining in a case of FL, due to a mutation in the part of BCL2 that encodes
Brand, M. van den +6 more
openaire +4 more sources
Venetoclax: Targeting BCL2 in Hematological Cancers
2018Over the last years, targeted anti-cancer therapy with small-molecule inhibitors and antibodies moved to the forefront as a strategy to treat hematological cancers. These novel agents showed outstanding effects in treatment of patients, often irrespective of their underlying genetic features.
Billy Michael Chelliah Jebaraj +2 more
openaire +3 more sources
Journal of the Chemical Society, Faraday Transactions, 1995
The fluorescence processes following vacuum-UV excitation of BCl3 in the photon range 9–25 eV have been studied using synchrotron radiation. Excitation spectra have been recorded at the UK Daresbury source with no dispersion of the fluorescence. Such spectra give information on the primary excitation process, i.e.
Richard P. Tuckett +7 more
openaire +2 more sources
The fluorescence processes following vacuum-UV excitation of BCl3 in the photon range 9–25 eV have been studied using synchrotron radiation. Excitation spectra have been recorded at the UK Daresbury source with no dispersion of the fluorescence. Such spectra give information on the primary excitation process, i.e.
Richard P. Tuckett +7 more
openaire +2 more sources
Science Signaling, 2008
Bcl2 is an oncogenic protein best known for its role as an inhibitor of apoptosis through its actions at the mitochondria. However, Bcl2 was initially identified as associated with a chromosomal breakpoint, not as a mitochondrial protein, which suggests that it has additional functions beyond those at the mitochondria.
openaire +2 more sources
Bcl2 is an oncogenic protein best known for its role as an inhibitor of apoptosis through its actions at the mitochondria. However, Bcl2 was initially identified as associated with a chromosomal breakpoint, not as a mitochondrial protein, which suggests that it has additional functions beyond those at the mitochondria.
openaire +2 more sources